Case Study: Type 2 Diabetes Reversal in a 55-Year-Old Man — Therapeutic Carbohydrate Restriction, Exercise Prescription, and Medication Deprescribing Using the Functional Health Matrix

Illustrative composite — not a single patient. This case study is a teaching composite synthesised from anonymised patterns in the published clinical literature, Nutri-Link case-history references, and the Stewart Nutrition practitioner reference guide for deficiency assessment. It does not describe a specific identifiable patient seen by Codenutri Ltd or any single practitioner. Names, demographic specifics, and quoted dialogue are constructed for educational illustration. Always work with a registered clinician for individual care. Editorial review by Chris Massamba, Dip CNM, FMCHC.

Key learning points

• Therapeutic carbohydrate restriction can produce clinically significant HbA1c reductions within weeks, but sulphonylurea and insulin secretagogue doses must be adjusted immediately to prevent hypoglycaemia — medication deprescribing is not optional; it is a safety requirement.
• Postprandial walking (10 minutes after each meal) is one of the most underutilised, evidence-based interventions in type 2 diabetes care, independently lowering post-meal glucose excursions by 12-22%.
• The combination of berberine, chromium picolinate, and magnesium addresses three distinct nodes of insulin resistance — hepatic glucose output, insulin receptor signalling, and intracellular glucose metabolism — and can be introduced safely alongside conventional pharmacotherapy under clinical supervision.
• Insulin resistance is a multi-system disorder: fatty liver, systemic inflammation, dyslipidaemia, and endothelial dysfunction are part of the same metabolic syndrome, not separate problems. Treating glucose in isolation misses the pathophysiology.
• Outcomes are illustrative and reflect composite patterns. Individual responses vary depending on diabetes duration, beta-cell reserve, medication burden, adherence, and practitioner oversight. Medication changes must be supervised by the prescribing clinician.

Patient Presentation

Robert (not his real name), a 55-year-old accountant from Manchester, presented to the clinic in April 2026 with an eight-year history of progressively worsening type 2 diabetes and what he described as "being on a conveyor belt to insulin."

His presenting complaint, in his own words: "I was diagnosed at 47. The GP said 'lose some weight, watch what you eat.' I tried, honestly I did. But every year the HbA1c goes up, and every year they add another tablet. I'm now on three diabetes medications, my blood sugars are still in double digits, and the diabetes nurse mentioned starting insulin at my last review. I'm tired all the time. My legs ache. I get up three times a night to pee. I've put on four stone since diagnosis. I've got grandchildren I want to run around with. I don't want to be injecting insulin for the rest of my life. Is there another way?"

Robert had been diagnosed with type 2 diabetes in 2018 at age 47 after a routine NHS health check identified a fasting glucose of 8.4 mmol/L and an HbA1c of 54 mmol/mol (7.1%). He was commenced on metformin 500 mg twice daily, titrated to 1 g twice daily over four weeks, and given standard dietary advice ("eat less sugar, reduce portion sizes") without referral to a dietitian.

Over the subsequent eight years, his glycaemic control deteriorated progressively. Gliclazide 80 mg twice daily was added in 2021 when his HbA1c reached 64 mmol/mol (8.0%). Sitagliptin 100 mg daily was added in 2024 when HbA1c reached 72 mmol/mol (8.7%). At presentation, despite triple oral therapy, his most recent HbA1c was 68 mmol/mol (8.4%) and his home fasting glucose readings ranged from 9.8 to 13.5 mmol/L.

Case snapshot: Robert, 55, accountant from Manchester. Eight-year history of T2D with progressive medication escalation. Triple oral therapy (metformin 2 g, gliclazide 160 mg, sitagliptin 100 mg daily) with HbA1c 68 mmol/mol. BMI 34.2, weight 108 kg, waist circumference 114 cm. Fatigue, nocturia, exertional dyspnoea, and peripheral paraesthesia. Facing insulin initiation.

Legend: This is an illustrative composite, not a single patient. Demographics and details are constructed for educational illustration.

Interpretation: A 55-year-old man with an eight-year trajectory of progressively worsening type 2 diabetes despite escalating pharmacotherapy, now facing insulin initiation. The pattern — progressive weight gain, worsening glycaemic control, and medication stacking without dietary intervention — reflects the limitations of a glucose-centric treatment paradigm that does not address the underlying insulin resistance driving the disease process (Taylor, 2013; Lean et al., 2018).

Robert's medication history included metformin hydrochloride 1 g twice daily (total 2 g; commenced 2018), gliclazide 80 mg twice daily (added 2021), and sitagliptin 100 mg once daily (added 2024). He also took atorvastatin 20 mg daily (commenced 2020) and ramipril 5 mg daily (commenced 2022 for borderline hypertension). His supplement history was minimal — occasional over-the-counter multivitamins without consistency. He had never received structured dietary education beyond a brief consultation at diagnosis.

His typical diet, captured in a three-day food diary, revealed: breakfast of white toast with margarine and jam, or sugary cereal with semi-skimmed milk; lunch of a sandwich, crisps, and a chocolate bar from the office canteen; evening meals of pasta, potatoes, or rice with meat and minimal vegetables; snacks of biscuits, cake, or fruit juice throughout the day; and 2-3 pints of beer on Friday and Saturday evenings. Estimated daily carbohydrate intake was 280-350 g, predominantly from refined sources. Fibre intake was estimated at 12-15 g/day — well below the SACN target of 30 g/day (SACN, 2015). Protein intake was approximately 0.8 g/kg body weight, predominantly at the evening meal.

Initial Clinical Assessment

Using a structured nutritional deficiency review — informed by the Stewart Nutrition practitioner reference (Stewart, 2024) and aligned with NICE Clinical Knowledge Summaries and NIH Office of Dietary Supplements guidance — a systematic assessment by body system was conducted:

General: Fatigue +++ — a pervasive, energy-sapping tiredness that worsened postprandially (suggesting reactive hypoglycaemia on a background of hyperinsulinaemia, as well as possible deficiencies in magnesium, B1, B12, and protein-energy). Weight gain was progressive — 25 kg over 8 years (BMI 34.2, waist circumference 114 cm, classifying as central obesity per NICE CG189). The patient reported "feeling heavy and sluggish all the time." Cold intolerance was absent. No pica, carotenoderma, or diffuse hyperpigmentation. Mild muscle wasting in the quadriceps (protein-energy, consistent with preferential visceral fat deposition and relative sarcopenia in metabolically unhealthy obesity).

Skin: Dry, rough skin over the shins and forearms (essential fatty acids). Acanthosis nigricans — a velvety, hyperpigmented thickening at the nape of the neck and axillae — a clinical marker of severe insulin resistance (Kahn and Flier, 2000). No excessive bruising, petechiae, or perifollicular haemorrhage. Slow wound healing reported — a minor shaving cut had taken three weeks to heal fully (zinc, vitamin C, protein-energy; also reflecting microvascular impairment from chronic hyperglycaemia).

Mouth: Angular cheilitis — cracking at the corners of the mouth (iron, vitamin B2). Dry mouth (xerostomia) — likely related to hyperglycaemia-induced polyuria and dehydration rather than a primary nutritional deficiency, though zinc deficiency can also contribute. No glossitis, oral ulceration, or gingival bleeding.

Nails: Brittle, flaking nails with longitudinal ridging (iron, essential fatty acids). No koilonychia.

Head, face, and neck: Scalp hair diffusely thinning — not frankly alopecic but noticeably reduced density over the vertex (iron, possibly zinc). Mild seborrhoeic dermatitis at the nasal alae and eyebrows (vitamin B2, vitamin B6, zinc). No goitre.

Musculoskeletal: Generalised muscle aching — "like I've been to the gym but I haven't" (magnesium, potassium, vitamin B1). Calf cramps 2-3 nights per week — a classic sign of magnesium insufficiency, exacerbated by the magnesium-depleting effects of thiazide-like diuretic use (ramipril alone is not a significant magnesium depleter, but poorly controlled diabetes increases urinary magnesium losses via osmotic diuresis). No difficulty rising from a chair, no waddling gait, no Chvostek's sign.

Neurological: Peripheral paraesthesia — tingling and numbness in both feet, described as "pins and needles that never quite go away" (vitamin B12, thiamine/benfotiamine, alpha-lipoic acid, magnesium — all relevant to diabetic peripheral neuropathy; also reflecting direct neuropathic damage from chronic hyperglycaemia and advanced glycation end-product accumulation). Brain fog — difficulty concentrating during afternoon meetings, described as "my brain goes into a fog about two hours after lunch" — strongly suggestive of postprandial hyperglycaemia driving cognitive impairment (Sommerfield et al., 2004). No orthostatic dizziness, no tremor.

Gastrointestinal: Constipation — bowel motions every 2-3 days, often hard and difficult to pass (magnesium, fibre, potassium, dehydration). Postprandial bloating after carbohydrate-heavy meals — suggestive of small intestinal bacterial overgrowth or carbohydrate maldigestion in the context of altered gut motility from autonomic neuropathy. No diarrhoea, no abdominal pain.

Conventional laboratory results (from GP records, three months prior to presentation):

• HbA1c: 68 mmol/mol (8.4%) — NICE target for T2D is 48-53 mmol/mol; this represents sustained poor glycaemic control on triple oral therapy
• Fasting glucose: 11.2 mmol/L (NICE diagnostic threshold for diabetes ≥7.0 mmol/L)
• Renal function: eGFR 82 mL/min/1.73m², creatinine 88 micromol/L — within normal limits
• Liver function: ALT 62 U/L (elevated; reference <45), AST 48 U/L (elevated; reference <40), GGT 95 U/L (elevated; reference <60) — consistent with non-alcoholic fatty liver disease (NAFLD), present in approximately 70% of individuals with T2D (Younossi et al., 2019)
• Lipid profile: total cholesterol 5.8 mmol/L, LDL 3.4 mmol/L, HDL 0.9 mmol/L (low; NICE target >1.0 for men), triglycerides 3.8 mmol/L (markedly elevated; NICE target <1.7) — the atherogenic dyslipidaemia pattern characteristic of insulin resistance: high triglycerides, low HDL, and atherogenic small dense LDL particles
• Full blood count: haemoglobin 148 g/L (normal), MCV 91 fL (normal), WCC 7.2 × 10⁹/L (normal)
• Ferritin: 218 ng/mL (elevated; optimal 50-150) — ferritin is an acute-phase reactant; elevation here reflects the systemic low-grade inflammation of metabolic syndrome rather than iron overload, though haemochromatosis should be excluded in the presence of NAFLD
• TSH: 2.4 mIU/L (within NHS reference range 0.27-4.2; functional optimal 1.0-2.0)
• Vitamin D (25-OH): 32 nmol/L (deficient by NICE standards <25 nmol/L but functionally inadequate; optimal >75 nmol/L per SACN, 2016)
• No assessment had been made of fasting insulin, HOMA-IR, magnesium status, vitamin B12, omega-3 index, or organic acids

The conventional workup had documented the consequences of prolonged metabolic dysfunction — NAFLD, atherogenic dyslipidaemia, and early microvascular changes — but had not interrogated the underlying drivers: the degree of insulin resistance, the pattern of postprandial glucose excursions, or the nutritional deficiencies perpetuating the metabolic dysfunction.

Clinical pearl: In type 2 diabetes, the conventional blood panel documents the damage (HbA1c, lipids, liver enzymes) without interrogating the driver (insulin resistance, measured by fasting insulin and HOMA-IR). A patient on three glucose-lowering medications with an HbA1c of 68 mmol/mol is not a "difficult-to-control diabetic" — they are an individual with severe insulin resistance whose treatment plan does not address the underlying pathophysiology. This pattern of escalating pharmacotherapy without dietary intervention is examined in Essential Functional Medicine Labs for 2026.

Functional Health Matrix Assessment

The patient was scored across all seven nodes of the Functional Health Matrix, where 1 represents severe dysfunction and 5 represents optimal function:

Total Initial Matrix Score: 14/35 — moderate-to-severe dysfunction centred on the Energy Production, Assimilation, Biotransformation, Defence & Repair, Transport, and Communication nodes. Only Structural Integrity remained relatively preserved. The matrix visualisation showed a broad, "hollowed-out" pattern — characteristic of metabolic syndrome where insulin resistance and systemic inflammation have compromised multiple nodes simultaneously, rather than the focal collapse pattern seen in post-viral syndromes.

Legend: Each node scored 1-5 (1 = severely compromised, 5 = optimal). Total out of 35. Clinical rationale documents the evidence for each score. The broad "hollowed-out" pattern defines metabolic syndrome: Energy Production is the primary crisis node, but the metabolic insult has radiated outward to compromise five additional nodes.

Interpretation: The FHM reveals a metabolic syndrome pattern distinct from post-viral or autoimmune presentations: Energy Production (1/5) is the core crisis node, but unlike long COVID where Structural Integrity and Transport are preserved, here the metabolic dysfunction has radiated outward to affect Assimilation (2/5), Biotransformation (2/5), Transport (2/5), Communication (2/5), and Defence & Repair (2/5). Only Structural Integrity (3/5) remains relatively intact. Treatment must target the root — insulin resistance — whilst simultaneously addressing the downstream consequences: NAFLD, dyslipidaemia, inflammation, and gut dysbiosis.

Figure: Functional Health Matrix — baseline assessment

Description: Radar chart showing 7 nodes with baseline scores. Energy Production (1/5) highlighted in red as primary therapeutic target. Assimilation (2/5), Biotransformation (2/5), Transport (2/5), Communication (2/5), and Defence & Repair (2/5) in amber. Structural Integrity (3/5) in pale green. The chart shows a broad collapse pattern characteristic of metabolic syndrome — the metabolic insult has radiated outward from the core to compromise the periphery.

Legend: Each node scored 1-5 (1 = severely compromised, 5 = optimal). Total out of 35. Nodes scoring 1-2 are primary therapeutic targets. The visual shows the multi-system impact of chronic insulin resistance.

Interpretation: The "hollowed-out" radar shape is characteristic of metabolic syndrome: six of seven nodes are compromised, with Energy Production at crisis level. This distinguishes metabolic syndrome from post-viral fatigue (where Energy and Communication collapse but Transport, Biotransformation, and Structural Integrity remain intact) and from autoimmune gut-driven cases (where Assimilation is typically at crisis level). In metabolic syndrome, the primary intervention must target insulin resistance at the Energy Production node — as this node improves, downstream nodes follow.

Wheel of Life Assessment

The patient was scored across all eight dimensions of the Wheel of Life, where 1 represents crisis and 10 represents thriving:

Total Initial Wheel of Life Score: 32/80 — pronounced imbalance across the physical health dimensions. Nutrition & Diet and Movement & Exercise were at crisis levels. Stress Management, Sleep & Recovery, and Spiritual Practice required significant attention. The preserved scores in Relationships and Purpose represented therapeutic resources — motivational anchors to leverage during the behaviour-change demands of the protocol.

Legend: Each dimension scored 1-10. Total out of 80. Lower scores indicate areas of significant lifestyle imbalance requiring attention alongside clinical interventions.

Interpretation: The wheel showed a characteristic metabolic syndrome pattern: the physical health dimensions (Nutrition 2/10, Movement 2/10) were at crisis levels, driven by decades of obesogenic environmental exposure. Sleep (4/10) was compromised by nocturia-driven fragmentation and likely undiagnosed OSA — both consequences of poorly controlled diabetes rather than primary sleep pathology. The preserved upper-half dimensions — Relationships (6/10), Environment (6/10), Purpose (5/10) — provided critical therapeutic leverage: Robert's identity as a grandfather and his supportive marriage were powerful intrinsic motivators that could sustain the behavioural demands of the protocol through difficult periods.

Figure: Wheel of Life — baseline assessment

Description: Radar chart showing 8 dimensions with baseline scores. Nutrition & Diet (2/10) and Movement & Exercise (2/10) highlighted in red. Stress Management (3/10), Sleep & Recovery (4/10), and Spiritual Practice (4/10) in amber. Purpose & Meaning (5/10), Relationships & Community (6/10), and Environment & Toxins (6/10) in pale green. The chart shows a collapsed lower half with a preserved upper half — physical health domains at crisis level whilst psychosocial resources remain intact.

Legend: Each dimension scored 1-10. Total out of 80. Lower scores indicate areas of significant lifestyle imbalance.

Interpretation: The wheel asymmetry — collapsed physical health, preserved psychosocial health — distinguishes metabolic syndrome from depression, where Purpose and Relationships typically collapse alongside physical dimensions. The preserved upper half provided the motivational architecture for recovery: Robert's identity as a grandfather was the emotional engine that could power sustained behaviour change.

Functional Testing Ordered

Based on the clinical presentation, matrix assessment, and the strong evidence base linking insulin resistance to multi-system metabolic dysfunction, the following investigations were ordered:

Fasting insulin and HOMA-IR:

• Fasting insulin: 28 mIU/L (markedly elevated; optimal <10 mIU/L)
• Fasting glucose: 11.2 mmol/L
• HOMA-IR: (28 × 11.2) / 22.5 = 13.9 (severe insulin resistance; optimal <1.0; values >2.5 indicate significant insulin resistance) — this confirmed that Robert's beta cells were producing enormous quantities of insulin, but his tissues were profoundly resistant to its signal

Comprehensive metabolic panel:

• HbA1c: 68 mmol/mol (8.4%) — confirmed on repeat testing
• Fructosamine: 385 micromol/L (elevated; reference 200-285) — providing a 2-3 week glycaemic average, useful for monitoring rapid changes once the intervention commenced
• Uric acid: 468 micromol/L (elevated; optimal <360) — hyperuricaemia is an independent predictor of metabolic syndrome progression and NAFLD severity; fructose metabolism generates uric acid as a by-product, and Robert's high sugar intake was a likely contributor
• hs-CRP: 6.8 mg/L (markedly elevated; optimal <1.0; cardiovascular risk category: high risk >3.0) — confirming the systemic inflammatory state of metabolic syndrome
• ALT: 62 U/L, AST: 48 U/L, GGT: 95 U/L — consistent with NAFLD; the AST/ALT ratio <1 suggests steatosis without significant fibrosis, though Fib-4 and NAFLD fibrosis scores should be calculated
• Lipid profile: total cholesterol 5.8 mmol/L, LDL 3.4 mmol/L, HDL 0.9 mmol/L, triglycerides 3.8 mmol/L, non-HDL cholesterol 4.9 mmol/L — the atherogenic dyslipidaemia triad (high triglycerides, low HDL, elevated small dense LDL) characteristic of insulin resistance

Nutritional status:

• Vitamin D (25-OH): 32 nmol/L — functionally deficient; optimal >75 nmol/L (SACN, 2016)
• RBC magnesium: 3.8 mg/dL (low; optimal 5.5-6.8 mg/dL) — magnesium is a cofactor for over 300 enzymatic reactions including tyrosine kinase activity at the insulin receptor; hypomagnesaemia is both a cause and consequence of insulin resistance (Veronese et al., 2016)
• Serum zinc: 10.8 micromol/L (low-normal; optimal 13-18 micromol/L) — zinc is essential for insulin synthesis, storage, and secretion in pancreatic beta cells, and for insulin receptor phosphorylation (Jansen, Karges and Rink, 2009)
• Vitamin B12: 312 pg/mL (borderline; functional optimal >500 pg/mL) — metformin is known to deplete B12 over time through altered ileal absorption; long-term B12 insufficiency can present as peripheral neuropathy, mimicking or compounding diabetic neuropathy
• Omega-3 index: 3.8% (low; optimal >8%; cardiovascular protection threshold >4%) — reflecting the low dietary intake of oily fish and the pro-inflammatory eicosanoid imbalance characteristic of the Western dietary pattern
• CoQ10 (plasma): 0.52 microg/mL (low-normal; statin therapy depletes CoQ10, and the combination of atorvastatin with pre-existing mitochondrial dysfunction from insulin resistance is a recognised cause of statin-associated muscle symptoms)

Adiponectin:

• Adiponectin: 4.2 microg/mL (low; optimal >10 microg/mL) — adiponectin is an insulin-sensitising adipokine; low levels are causally associated with insulin resistance, NAFLD progression, and cardiovascular risk in T2D (Li et al., 2009)

The testing revealed a coherent pathophysiological narrative: eight years of a high-glycaemic-load dietary pattern had driven progressively worsening insulin resistance (HOMA-IR 13.9), which in turn had produced NAFLD (elevated transaminases, low adiponectin), atherogenic dyslipidaemia (high triglycerides, low HDL), systemic inflammation (hs-CRP 6.8 mg/L), and multiple nutritional insufficiencies (magnesium, zinc, vitamin D, B12, omega-3, CoQ10) — each of which independently worsened insulin signalling and created a self-reinforcing cycle of metabolic dysfunction. The conventional pharmacotherapy (metformin, gliclazide, sitagliptin) had attempted to control blood glucose downstream of this dysfunction without addressing the upstream drivers: the dietary pattern, the insulin resistance, and the nutritional deficiencies.

Intervention Protocol

The protocol was structured in three phases over twelve weeks, targeting insulin resistance at its root — the dietary pattern — whilst providing the nutritional cofactors necessary for insulin signalling, mitochondrial function, and metabolic repair. All medication changes were implemented under the supervision of the patient's GP, with explicit communication at each stage.

Phase 1: Stabilise Blood Glucose and Initiate Medication Deprescribing (Weeks 1-4)

The first phase focused on rapidly reducing the glycaemic load driving hyperinsulinaemia and hyperglycaemia, whilst initiating the deprescribing of medications that posed a safety risk once blood glucose began to fall.

Dietary intervention — therapeutic carbohydrate restriction: The principal intervention was a therapeutic carbohydrate-restricted diet, initially set at <80 g total carbohydrate per day, distributed across two to three meals. This threshold was chosen based on the evidence that carbohydrate intake below 130 g/day produces clinically significant HbA1c reductions in T2D, with more aggressive restriction (<50-80 g/day) producing larger and more rapid improvements in glycaemic control and enabling medication reduction (Goldenberg et al., 2021; Durrer Schutz et al., 2021). Protein was increased to 1.4-1.6 g/kg body weight (approximately 110-125 g daily for Robert's 80 kg lean mass estimate), distributed evenly across meals to support satiety, preserve lean mass, and provide gluconeogenic substrate that would not produce postprandial hyperglycaemia. Healthy fats — extra-virgin olive oil, avocados, nuts, seeds, oily fish — were encouraged ad libitum to provide energy substrate, support fat-soluble vitamin absorption, and enhance meal satisfaction.

A practical food guide replaced the abstract concept of "carbohydrate counting": the plate model specified half the plate as non-starchy vegetables (leafy greens, cruciferous vegetables, salad), a quarter as protein (meat, fish, eggs, tofu), and a quarter as either starchy vegetables (sweet potato, parsnips) or legumes, with added healthy fats. Ultra-processed foods, sugar-sweetened beverages, fruit juices, white bread, pasta, rice, potatoes, breakfast cereals, biscuits, cakes, and confectionery were eliminated entirely.

Postprandial walking: Robert was instructed to walk for 10 minutes immediately after each meal — breakfast, lunch, and dinner. Postprandial walking attenuates post-meal glucose excursions by 12-22% through contraction-mediated GLUT4 translocation — an insulin-independent pathway that bypasses the signalling defect at the root of T2D (Reynolds et al., 2016; DiPietro et al., 2013). This intervention requires no equipment, no gym membership, and no dedicated time beyond ten minutes, making it one of the most practical and underutilised tools in diabetes care. Robert's initial step count target was 5,000 steps daily, achievable through three postprandial walks (approximately 1,500-2,000 steps each) plus incidental movement.

Medication deprescribing — Phase 1: A letter was sent to Robert's GP before the first week, explaining the planned dietary intervention and the rationale for proactive medication adjustment. The key safety concern was gliclazide, a sulphonylurea that stimulates endogenous insulin secretion independently of blood glucose. When carbohydrate intake is substantially reduced, blood glucose falls — but gliclazide continues to stimulate insulin release, creating a significant risk of hypoglycaemia.

The GP agreed to discontinue gliclazide 80 mg twice daily at the start of the dietary intervention (week 1). Metformin 1 g twice daily and sitagliptin 100 mg once daily were continued initially, with a plan to review after four weeks. Robert was provided with a blood glucose monitor and instructed to test fasting and two-hour postprandial glucose daily, emailing results weekly. He was educated on hypoglycaemia recognition and management and provided with an emergency contact protocol.

Supplementation initiated:

• Berberine HCl: 500 mg three times daily before meals. Rationale: Berberine is an isoquinoline alkaloid that activates AMPK — the same cellular energy sensor targeted by metformin — reducing hepatic gluconeogenesis, increasing skeletal muscle glucose uptake, and improving insulin sensitivity through multiple mechanisms including modulation of gut microbiota and inhibition of intestinal disaccharidases. A 2015 meta-analysis of 27 RCTs (n = 2,569) demonstrated that berberine reduced HbA1c by 0.63% (7 mmol/mol) and fasting glucose by 0.86 mmol/L compared to placebo or no treatment, with effects comparable to oral hypoglycaemic agents when combined with lifestyle modification (Lan et al., 2015). The pre-meal timing allows berberine to inhibit carbohydrate breakdown in the gut, reducing the postprandial glucose load.
• Magnesium glycinate: 200 mg elemental magnesium twice daily (total 400 mg). Rationale: Magnesium is an obligate cofactor for the insulin receptor tyrosine kinase — the enzyme that phosphorylates the insulin receptor and initiates the intracellular signalling cascade (Veronese et al., 2016). Hypomagnesaemia — confirmed by Robert's RBC magnesium of 3.8 mg/dL — impairs insulin signalling at its most proximal step, rendering downstream interventions less effective. A pooled analysis of 24 RCTs demonstrated that magnesium supplementation significantly reduced fasting glucose, HbA1c, and HOMA-IR in T2D (Veronese et al., 2022). The glycinate form was selected for superior bioavailability and the additional glycine-mediated benefit for sleep quality.
• Chromium picolinate: 200 microg twice daily (total 400 microg). Rationale: Chromium is a component of chromodulin, an oligopeptide that amplifies insulin receptor signalling by enhancing tyrosine kinase activity. A 2024 systematic review of chromium supplementation in T2D reported mixed but generally positive effects on fasting glucose and HbA1c, with effects most pronounced in individuals with poor baseline glycaemic control — precisely the population Robert represents (Georgaki et al., 2024). The picolinate form was selected for its well-established bioavailability.
• Vitamin D3: 5,000 IU daily with vitamin K2 (100 microg as menaquinone-7). Rationale: Vitamin D modulates insulin secretion and sensitivity, and deficiency is a recognised risk factor for T2D progression (Pittas et al., 2019). Robert's 25(OH)D of 32 nmol/L was functionally deficient. A loading dose of 5,000 IU daily was selected to raise levels into the optimal range (>75 nmol/L), with K2 added to direct calcium to bone and away from vascular tissue — a consideration in a patient with existing cardiovascular risk factors. For further context on vitamin D dosing, see Vitamin D Reset: Obesity-Adjusted Dosing.
• Omega-3 fatty acids (EPA/DHA): 2 g total daily (1.2 g EPA, 0.8 g DHA). Rationale: Robert's omega-3 index of 3.8% reflected a profound deficit with pro-inflammatory consequences. Omega-3 fatty acids improve the lipid profile (particularly triglycerides), reduce systemic inflammation, and may modestly improve insulin sensitivity through PPAR-gamma activation and adiponectin upregulation.

Safety note: Sulphonylureas (gliclazide) and meglitinides stimulate insulin secretion independently of prevailing blood glucose. When therapeutic carbohydrate restriction is initiated, blood glucose falls rapidly — often within 48-72 hours. If sulphonylurea doses are not proactively reduced or discontinued, the patient is at risk of hypoglycaemia. This is a safety requirement, not an optional consideration. Always communicate with the prescribing clinician before initiating carbohydrate restriction in patients taking insulin secretagogues or insulin.

Phase 2: Enhance Insulin Sensitivity and Repair Metabolic Infrastructure (Weeks 5-8)

With blood glucose stabilising and the dietary pattern established, Phase 2 expanded the exercise prescription and added targeted supplements to accelerate insulin sensitisation and address the downstream consequences of eight years of metabolic dysfunction.

Exercise prescription — progression: Daily step count was increased to a minimum of 8,000 steps, achieved through postprandial walking (now 15 minutes after meals) plus a dedicated 30-minute walk each day. Additionally, resistance training was introduced twice weekly: a 30-minute bodyweight programme (squats, lunges, press-ups against a wall, seated rows with resistance bands, planks) designed to be performed at home without equipment. The rationale for prioritising resistance training alongside aerobic walking is that skeletal muscle is the body's largest glucose sink — approximately 80% of postprandial glucose disposal occurs in skeletal muscle, mediated by GLUT4 translocation (DeFronzo and Tripathy, 2009). Increasing muscle mass and insulin-independent GLUT4 translocation through resistance training directly addresses the core defect of T2D: impaired insulin-mediated glucose uptake. A 2007 JAMA trial demonstrated that combined aerobic and resistance training reduced HbA1c by 0.97% compared to non-exercising controls — an effect size comparable to adding a second oral hypoglycaemic agent (Sigal et al., 2007).

Dietary refinement: Carbohydrate intake was maintained at <80 g/day with an emphasis on carbohydrate quality: all carbohydrate sources were now from non-starchy vegetables, small portions of legumes, nuts, seeds, and occasional berries. Protein remained at 1.4-1.6 g/kg. Fibre intake increased to >25 g/day through the vegetable and legume emphasis. Alcohol was reduced to <4 units/week — a single glass of red wine with the Saturday evening meal — to reduce hepatic metabolic burden.

Supplementation — continued from Phase 1, plus:

• R-Alpha-lipoic acid (R-ALA): 300 mg twice daily (total 600 mg). Rationale: Alpha-lipoic acid is a mitochondrial cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase — two rate-limiting enzymes of the citric acid cycle — and a potent antioxidant that regenerates glutathione, vitamin C, and vitamin E. A 2023 umbrella review of ALA in metabolic disease confirmed significant improvements in insulin sensitivity (HOMA-IR), fasting glucose, and lipid profiles, with effects most pronounced in T2D populations (Capece et al., 2023). The R-isomer was selected for superior bioavailability. Additionally, ALA has an established evidence base for diabetic peripheral neuropathy — relevant to Robert's foot paraesthesia — with a 600 mg daily dose improving neuropathic symptoms by approximately 50% in the SYDNEY and NATHAN trials (Ziegler et al., 2011).
• Benfotiamine: 300 mg twice daily (total 600 mg). Rationale: Benfotiamine is a fat-soluble thiamine (vitamin B1) analogue with significantly higher bioavailability than water-soluble thiamine salts. It activates transketolase, which diverts glycolytic intermediates away from four damaging pathways activated by hyperglycaemia: the polyol pathway, advanced glycation end-product (AGE) formation, protein kinase C activation, and the hexosamine pathway (Hammes et al., 2003). A landmark 2006 study demonstrated that benfotiamine reduced AGE formation by 40% and prevented both macro- and microvascular endothelial dysfunction following an AGE-rich meal in individuals with T2D (Stirban et al., 2006). This mechanism — inhibiting the downstream damage of hyperglycaemia whilst the dietary intervention addresses the upstream cause — is complementary and clinically valuable.

Supplement schedule — Phase 2:

Medication deprescribing — Phase 2: At the week 4 review, Robert's average fasting glucose had fallen from 11.2 to 6.4 mmol/L, and his two-hour postprandial readings averaged 7.8 mmol/L. His GP agreed to discontinue sitagliptin 100 mg daily at this point (week 5), leaving metformin 1 g twice daily as his sole glucose-lowering agent. The DPP-4 inhibitor was deprescribed second because, once the dietary intervention had substantially reduced the glucose load entering the bloodstream, the incremental benefit of prolonging endogenous GLP-1 activity was diminished. Metformin was retained for its AMPK-activating, hepatic glucose output-reducing effects — which complemented rather than duplicated the dietary intervention — and for its well-established cardiovascular safety profile.

Phase 3: Rebalance and Sustain (Weeks 9-12)

The final phase consolidated the metabolic gains, expanded the exercise prescription to its maintenance level, implemented Wheel of Life improvements, and completed the medication deprescribing protocol.

Exercise prescription — maintenance: Resistance training was increased to three sessions weekly, incorporating progressive overload — resistance bands were upgraded, and dumbbells were introduced for goblet squats, bent-over rows, and overhead presses. Daily step count was maintained at >10,000 steps. One weekly session was dedicated to higher-intensity interval walking — alternating three minutes of brisk walking with two minutes of recovery pace for a total of 30 minutes — based on evidence that high-intensity interval training (HIIT) produces superior improvements in HbA1c, cardiorespiratory fitness, and body composition compared to continuous moderate-intensity exercise in T2D (Little et al., 2011; Grace et al., 2017).

Dietary consolidation: Carbohydrate intake was slightly liberalised to <100 g/day in week 10, once insulin sensitivity had demonstrably improved, to assess individual carbohydrate tolerance. The emphasis remained on carbohydrate quality — all carbohydrates from whole-food sources. Protein was maintained at 1.4-1.6 g/kg. Alcohol was eliminated entirely during weeks 9-12 to maximise hepatic recovery.

Wheel of Life interventions:

• Sleep & Recovery: Robert was referred for a home sleep apnoea test, which confirmed moderate OSA (AHI 22 events/hour). He was commenced on CPAP therapy at week 11, with notable improvements in sleep quality, daytime alertness, and morning fasting glucose (OSA treatment independently improves insulin sensitivity through reduced nocturnal sympathetic activation). His sleep hygiene was addressed: a consistent 22:30 bedtime, no screens after 21:30, and a 10-minute evening wind-down routine (reading, not work emails). Magnesium glycinate, already in the supplement protocol, provided additional sleep support through glycine's inhibitory neurotransmitter effects. For further context, see the companion article on sleep architecture and metabolic health.
• Stress Management: A 5-minute morning breathing practice (box breathing: 4-second inhale, 4-second hold, 4-second exhale, 4-second hold, repeated for 5 cycles) was introduced as a daily parasympathetic activation tool. Robert reported this was "surprisingly helpful — it's the first time I've sat still without my phone in years." An after-lunch 10-minute walk — already part of the protocol — doubled as a stress-management intervention, removing him from his desk and providing a natural transition between morning and afternoon work.
• Purpose & Meaning: Robert's identity as a grandfather was explicitly integrated into the protocol. His weekly goals were framed in terms of functional capacity with his grandchildren — "by week 12, you'll be able to play 20 minutes of football in the garden without stopping" — rather than abstract metrics. This "future-self" visualisation is a behaviour-change technique with demonstrated efficacy in health behaviour maintenance.

Medication deprescribing — Phase 3: At the week 8 review, Robert's HbA1c had fallen from 68 to 48 mmol/mol (8.4% to 6.5%) — a 20 mmol/mol reduction in eight weeks. His GP agreed to reduce metformin from 1 g twice daily to 500 mg twice daily (week 10), with a plan to consider complete discontinuation at three months if glycaemic control remained stable. Atorvastatin 20 mg was continued for its established cardiovascular benefit; ramipril 5 mg was reduced to 2.5 mg at week 10 as blood pressure had normalised (averaging 126/78 mmHg). The deprescribing timeline was:

Clinical safety note: All medication changes in this composite case were implemented under the supervision of the patient's GP. Medication deprescribing in T2D requires close monitoring — particularly when sulphonylureas or insulin are involved — and must never be undertaken without communication with the prescribing clinician. The speed of glycaemic improvement with carbohydrate restriction can be dramatic; proactive medication adjustment prevents hypoglycaemia rather than responding to it after it occurs.

Outcomes at 12 Weeks

Robert returned for his final assessment at week 12. The outcomes exceeded both the clinical team's expectations and the patient's:

Glycaemic control:

Robert's HbA1c of 42 mmol/mol at week 12 placed him below the diagnostic threshold for diabetes (≥48 mmol/mol) and within the prediabetic range (42-47 mmol/mol) — consistent with the definition of diabetes remission used in the DiRECT trial: HbA1c <48 mmol/mol off all glucose-lowering medications for at least two months (Lean et al., 2018). His HOMA-IR reduction from 13.9 to 1.7 represented an 88% improvement in insulin sensitivity — the physiological foundation beneath the numerical HbA1c improvement.

Anthropometric and metabolic:

The 16 kg weight loss (14.8% of body weight) is significant because the DiRECT trial demonstrated that remission becomes increasingly likely above 10 kg weight loss and highly probable above 15 kg — the "personal fat threshold" hypothesis (Taylor, 2013; Lean et al., 2018). The normalisation of ALT and AST, combined with the near-normalisation of GGT, indicated substantial resolution of hepatic steatosis — the liver, freed from the constant lipogenic stimulus of hyperinsulinaemia and dietary fructose, had begun to export its accumulated triglycerides. The triglyceride reduction from 3.8 to 1.6 mmol/L represented a 58% improvement — one of the most rapid and dramatic lipid responses achievable through dietary intervention, independent of statin therapy.

Nutritional status:

Symptom resolution:

• Nocturia: Resolved entirely by week 3 — Robert reported sleeping through the night for the first time in years, a change he described as "genuinely life-changing."
• Peripheral paraesthesia: Reduced by approximately 70% — the constant "pins and needles" had been replaced by occasional mild tingling in the toes only, with subjective improvement beginning around week 6 and steadily progressing.
• Fatigue: Resolved — Robert described having "energy I haven't felt in a decade" by week 8, with the postprandial "2 pm crash" eliminated by the dietary changes.
• Constipation: Resolved — bowel motions daily, well-formed, easy to pass (attributed to increased fibre, magnesium, and hydration).
• Exertional dyspnoea: Resolved — Robert could now climb three flights of stairs without stopping and played 20 minutes of football with his grandchildren without needing to rest.

Medication status at week 12:

• Metformin: 500 mg twice daily (reduced from 1 g twice daily)
• Ramipril: 2.5 mg daily (reduced from 5 mg daily)
• Atorvastatin: 20 mg daily (continued)
• Gliclazide: discontinued
• Sitagliptin: discontinued

Patient testimonial: "When the diabetes nurse mentioned insulin, something snapped. I thought: there has to be another way. I found the first week difficult — I won't pretend otherwise. I missed my toast, my biscuits, my evening beer. But when I saw my blood glucose readings falling within three days — from 12 to 7, then to 6 — I knew something real was happening. By week three, I was sleeping through the night for the first time in years. By week six, my trousers didn't fit. By week twelve, I played football in the garden with my grandkids and didn't stop once. My GP said my HbA1c is now in the prediabetic range. I'm not 'a diabetic who's controlling it well' — I'm someone who reversed it. That's a different thing entirely. That's hope."

Functional Health Matrix — Re-assessment at Week 12

Total Week 12 Matrix Score: 29/35 — a 15-point improvement (107% increase). The core achievement was the three-point improvement in Energy Production — reversing severe insulin resistance — which then cascaded into improvements across every other node. Notably, Assimilation improved by three points as well, reflecting the profound impact of the dietary intervention on the gut ecosystem: the same dietary pattern that reduced glycaemic load simultaneously provided the fibre and polyphenol substrate necessary for a healthy gut microbiome.

Legend: Each node re-scored using the same 1-5 scale (1 = severely compromised, 5 = optimal). The 107% overall improvement reflects the broad, multi-system impact of addressing insulin resistance at its root rather than managing blood glucose as an isolated endpoint.

Interpretation: The matrix transformation reflects a core principle of functional medicine: address the root driver, and downstream nodes follow. Energy Production, the primary crisis node at baseline (1/5), improved to 4/5 — and every other node followed. The most dramatic collateral improvements were in Assimilation (2→5) — reflecting the gut-health benefits of a whole-food, high-fibre dietary pattern — and Defence & Repair (2→4) — reflecting the resolution of systemic inflammation. Only Structural Integrity, which was already the best-preserved node at baseline (3/5), showed a modest single-point improvement.

Figure: Functional Health Matrix — before and after

Description: Dual radar chart showing baseline and week 12 scores across all 7 nodes. Baseline scores (hollow radar) in amber/red tones showing the broad collapsed pattern of metabolic syndrome. Week 12 scores (filled radar) in green tones showing substantial expansion across all nodes. Energy Production highlighted with a "+3" annotation. The visual transformation illustrates the cascading effect of addressing the root driver (insulin resistance) on downstream nodes.

Legend: Each node scored 1-5. Total out of 35. The before-and-after visual illustrates the reversal of the metabolic syndrome pattern described at baseline — improvement in the core Energy Production node radiates outward to every other node.

Interpretation: The dual radar chart shows the characteristic response to dietary-first metabolic intervention: the core node (Energy Production) improves dramatically, and because insulin resistance is a systemic driver, the improvement cascades to every other node. This distinguishes dietary-first interventions from pharmacotherapy alone, which may improve Energy Production (HbA1c) without addressing Assimilation, Defence & Repair, or Biotransformation.

Wheel of Life — Re-assessment at Week 12

Total Week 12 Wheel of Life Score: 55/80 — a 23-point improvement (72% increase). The most dramatic improvements were in Nutrition & Diet (+6) and Movement & Exercise (+5) — the two dimensions that had been at crisis level at baseline and that were most directly targeted by the intervention. Sleep & Recovery (+3) and Stress Management (+3) showed substantial improvement driven by both the direct interventions (breathing, sleep hygiene, CPAP) and the indirect benefits of metabolic normalisation (nocturia resolution, reduced anxiety).

Legend: Each dimension re-scored using the same 1-10 scale. The 72% overall improvement reflects the behavioural and lifestyle transformation that accompanied — and sustained — the metabolic improvements documented in the clinical outcomes.

Interpretation: The wheel transformation illustrates the bidirectional relationship between metabolic health and lifestyle behaviour: the dietary intervention improved metabolic health, which improved sleep and energy, which enabled exercise, which further improved metabolic health — a virtuous cycle replacing the vicious cycle that had driven eight years of progressive decline.

Clinical Pearls

1. Therapeutic carbohydrate restriction works quickly — adjust medications proactively. When carbohydrate intake is substantially reduced, blood glucose falls within 48-72 hours. Sulphonylureas (e.g., gliclazide) and insulin secretagogues must be reduced or discontinued at the point of dietary change, not after hypoglycaemia occurs. Write to the patient's GP before starting. This is a safety requirement, not a clinical nuance.
2. Postprandial walking is the most underutilised intervention in diabetes care. Ten minutes of walking after each meal activates GLUT4 translocation through an insulin-independent pathway — bypassing the signalling defect at the heart of T2D. It requires no equipment, no prescription, and no dedicated time beyond what most people already spend scrolling their phones after eating. The evidence is robust (Reynolds et al., 2016; DiPietro et al., 2013) and the clinical effect is immediate. Prescribe it explicitly.
3. Insulin resistance is a nutritional deficiency state. The same metabolic dysfunction that impairs glucose disposal also impairs the absorption, transport, and cellular utilisation of magnesium, zinc, chromium, vitamin D, and B vitamins. Correcting these deficiencies is not optional — it is a prerequisite for insulin signalling to function. Magnesium, in particular, is the obligate cofactor for the insulin receptor tyrosine kinase. Supplementing berberine or exercising to improve insulin sensitivity without first ensuring magnesium adequacy is like trying to start a car with a flat battery.
4. The personal fat threshold is a clinically useful concept. The DiRECT trial demonstrated that type 2 diabetes remission becomes probable above 10-15 kg weight loss because excess ectopic fat — particularly in the liver and pancreas — is the proximate cause of the beta-cell dysfunction and hepatic insulin resistance that define T2D (Taylor, 2013). Robert's 16 kg weight loss crossed this threshold, and his metabolic outcomes — normalised ALT, dramatically improved HOMA-IR, HbA1c below the diagnostic threshold — reflected it. Frame weight loss not as an aesthetic goal but as a metabolic intervention: "every kilogram lost is reducing the fat clogging your liver and pancreas."

Internal navigation

• The 5R Gut Protocol: 2026 Update — Microbiome-Targeted Reinoculation — the gut-health dimension of metabolic restoration; Robert's Assimilation node improvement from 2/5 to 5/5 reflected the profound impact of dietary change on the gut ecosystem.
• Essential Functional Medicine Labs for 2026 — the testing framework that informed this case; fasting insulin, HOMA-IR, and RBC magnesium should be standard in every T2D workup.
• Dietary Guidance 2025-2030: A Functional Medicine Alignment — the dietary principles underlying the therapeutic carbohydrate restriction protocol, including the evidence base for protein prioritisation and fibre targets.
• Late-Spring Vitamin D Reset: Obesity-Adjusted Dosing in Functional Medicine — the rationale for Robert's 5,000 IU daily vitamin D3 dosing, contextualised within obesity-adjusted requirements.
• CGM in Functional Practice: When Continuous Glucose Monitoring Adds Clinical Value — for practitioners considering CGM as an adjunct to the dietary intervention described in this case; real-time glucose feedback accelerates dietary learning.

When the clinical picture is complex and polypharmacy is involved, please work with a registered practitioner. Find an EPINUTRI practitioner.